Press Releases

 
Press Releases
  Date Title View
Feb 14, 2018
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta (fluticasone furoa...
Feb 8, 2018
Royalties earned of $70.5 million in the fourth quarter of 2017, up 51% from the fourth quarter of 2016. Royalties earned in 2017 reached $227.9 million, up 56% from 2016. Net income attributable to Innoviva stockholders of $58.4 million for the fourth quarter of 20...
Feb 2, 2018
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at ...
Jan 26, 2018
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a label update for the use of once-daily Rel...
Dec 19, 2017
Appoints George Bickerstaff, III and Odysseas Kostas, M.D. to the Board BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today announced it implemented the Delaware Court of Chancery's order enforcing the oral settlement agreement with ...
Nov 23, 2017
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, &#...
Nov 16, 2017
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI') as a maintenance treatm...
Nov 1, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that management will present at the following healthcare-focused investment banking conferences in November 2017: Credit Suisse 26th Annual Healthcare ConferenceNovember 8, 2017 at 12:20 pm MTScottsdale, Ari...
Nov 1, 2017
LONDON--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA) fixed-dose combination, Anoro Ellipta (umeclidinium/vilanterol 6...
Oct 25, 2017
Royalties earned in the third quarter of 2017 of $51.9 million, up 42% from the third quarter of 2016. Completed the full refinancing of the 9% non-recourse term notes due 2029. Plans to repurchase up to $80 million of common stock, pursuant to an acceler...
1
...
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$15.05 0.28 (1.90%) 09/18/18 4:00 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.